| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Eslicarbazepine |
| Brand | Zebinix® |
| Indication | For the treatment of Epilepsy |
| Assessment Process | |
| Rapid review commissioned | 01/08/2009 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
* Company did not submit, Eslicarbazepine (Zebinix®) was reimbursed under the Community Drugs Schemes following introduction of a Patient Access Scheme.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
